Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brincidofovir in Post-Transplant Subjects With BK Virus Viruria
NCT00793598Phase 2
Key facts
- Status
- Completed
- Start
- Nov 2009
- Primary completion
- Oct 2010
- Countries
- 1
- Sponsor
- Chimerix Inc.
- Modality
- Metabolically Activated Prodrugs
- Drugs
- brincidofovir
- Conditions
- BK virus infection
01
Overview
Phase 2, randomised, double-blind trial in BK virus infection comparing Brincidofovir with Placebo (2 arms). Primary endpoint: Number of Adverse Events at 35 days. Started Nov 2009; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Brincidofovir
Experimental arm receiving various doses of BCV
Placebo
Placebo comparator arm
03
Endpoints
Primary
Number of Adverse Events
Secondary
Percentage of Patients Who Achieved BK Viruria Resolution
Number of Patients Who Achieved a Clinically Significant Decrease in BK Viruria
Beyond the preview
Go deeper on NCT00793598.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00793598.